Molecularly targeted drugs for metastatic colorectal cancer

References

• Jemal A Center MM DeSantis C Ward EM Global patterns of cancer incidence and mortality rates and trends Cancer Epidemiol Biomarkers Prev 2010 19 8 1893 1907 20647400
   PubMed Web of Science ®Google Scholar
• Dai Z Zheng RS Zou XN Analysis and prediction of colorectal cancer incidence trend in China Zhonghua Yu Fang Yi Xue Za Zhi 2012 46 598 603 Chinese 22943913
   PubMedGoogle Scholar
• Globocan 2008 cancer fact sheet [webpage on the Internet] Lyon IARC 2010 Available from: http://globocan.iarc.fr/factsheets/cancers/colorectal.asp Accessed August 15, 2013
   Google Scholar
• Van Cutsem E Nordlinger B Cervantes A ESMO Guidelines Working Group Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment Ann Oncol 2010 21 Suppl 5 v93 v97 20555112
   PubMed Web of Science ®Google Scholar
• André T Louvet C Maindrault-Goebel F CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR Eur J Cancer 1999 35 1343 1347 10658525
   PubMed Web of Science ®Google Scholar
• Cheeseman SL Joel SP Chester JD A ‘modified de Gramont’ regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer Br J Cancer 2002 87 393 399 12177775
   PubMed Web of Science ®Google Scholar
• Goldberg RM Sargent DJ Morton RF A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer J Clin Oncol 2004 22 23 30 14665611
   PubMed Web of Science ®Google Scholar
• Grothey A Sargent D Goldberg RM Schmoll HJ Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment J Clin Oncol 2004 22 1209 1214 15051767
   PubMed Web of Science ®Google Scholar
• Grothey A Sugrue MM Purdie DM Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE) J Clin Oncol 2008 26 5326 5334 18854571
   PubMed Web of Science ®Google Scholar
• Scott LJ Bevacizumab: in first-line treatment of metastatic breast cancer Drugs 2007 67 1793 1799 17683175
   PubMed Web of Science ®Google Scholar
• Zhu Z Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives Acta Pharmacol Sin 2007 28 1476 1493 17723181
   PubMed Web of Science ®Google Scholar
• Edwards MS Chadda SD Zhao Z Barber BL Sykes DP A systematic review of treatment guidelines for metastatic colorectal cancer Colorectal Dis 2012 14 e31 e47 21848897
   PubMed Web of Science ®Google Scholar
• Regorafenib FAf Previously Treated Metastatic Colorectal Cancer http://en.wikipedia.org/wiki/RegorafenibAccessed October 15, 2013
   Google Scholar
• Stevenson CE Nagahashi M Ramachandran S Yamada A Bear HD Takabe K Bevacizumab and breast cancer: what does the future hold? Future Oncol 2012 8 403 414 22515444
   PubMed Web of Science ®Google Scholar
• Rodgers M Soares M Epstein D Yang H Fox D Eastwood A Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer Health Technol Assess 2011 15 Suppl 1 1 12 21609648
   PubMed Web of Science ®Google Scholar
• Miles D Zielinski C Martin M Vrdoljak E Robert N Combining capecitabine and bevacizumab in metastatic breast cancer: a comprehensive review Eur J Cancer 2012 48 482 491 22257791
   PubMed Web of Science ®Google Scholar
• Narita Y Drug review: safety and efficacy of bevacizumab for glioblastoma and other brain tumors Jpn J Clin Oncol 2013 43 587 595 23585688
   PubMed Web of Science ®Google Scholar
• Rahmathulla G Hovey EJ Hashemi-Sadraei N Ahluwalia MS Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges Onco Targets Ther 2013 6 371 389 23620671
   PubMed Web of Science ®Google Scholar
• Soria JC Mauguen A Reck M meta-analysis of bevacizumab in advanced NSCLC collaborative group Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer Ann Oncol 2013 24 20 30 23180113
   PubMed Web of Science ®Google Scholar
• Planchard D Bevacizumab in non-small-cell lung cancer: a review Expert Rev Anticancer Ther 2011 11 1163 1179 21916570
   PubMed Web of Science ®Google Scholar
• Melichar B Procházková-Študentová H Vitásková D Bevacizumab in combination with IFN-alpha in metastatic renal cell carcinoma: the AVOREN trial Expert Rev Anticancer Ther 2012 12 1253 1261 23136836
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G Porta C Bellmunt J Toxicities of targeted therapy and their management in kidney cancer Eur Urol 2011 59 526 540 21277078
   PubMed Web of Science ®Google Scholar
• Garcia A Singh H Bevacizumab and ovarian cancer Ther Adv Med Oncol 2013 5 133 141 23450196
   PubMed Web of Science ®Google Scholar
• Miyake TM Sood AK Coleman RL Contemporary use of bevacizumab in ovarian cancer Expert Opin Biol Ther 2013 13 283 294 23190436
   PubMed Web of Science ®Google Scholar
• Eskander RN Randall LM Bevacizumab in the treatment of ovarian cancer Biologics 2011 5 1 5 21383911
   PubMedGoogle Scholar
• Yeung Y Tebbutt NC Bevacizumab in colorectal cancer: current and future directions Expert Rev Anticancer Ther 2012 12 1263 1273 23113577
   PubMed Web of Science ®Google Scholar
• Whyte S Pandor A Stevenson M Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal Pharmacoeconomics 2012 30 1119 1132 23058097
   PubMed Web of Science ®Google Scholar
• Strickler JH Hurwitz HI Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer Oncologist 2012 17 513 524 22477726
   PubMed Web of Science ®Google Scholar
• Grothey A Galanis E Targeting angiogenesis: progress with anti-VEGF treatment with large molecules Nat Rev Clin Oncol 2009 6 507 518 19636328
   PubMed Web of Science ®Google Scholar
• Shibuya M Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases J Biochem 2013 153 13 19 23172303
   PubMed Web of Science ®Google Scholar
• Giacca M Zacchigna S VEGF gene therapy: therapeutic angiogenesis in the clinic and beyond Gene Ther 2012 19 622 629 22378343
   PubMed Web of Science ®Google Scholar
• Wang L Zeng H Wang P Soker S Mukhopadhyay D Neuropilin-1-mediated vascular permeability factor/vascular endothelial growth factor-dependent endothelial cell migration J Biol Chem 2003 278 48848 48860 14514674
   PubMed Web of Science ®Google Scholar
• Giuliano S Pages G Mechanisms of resistance to anti-angiogenesis therapies Biochimie 2013 95 1110 1119 23507428
   PubMed Web of Science ®Google Scholar
• Moreno Garcia V Basu B Molife LR Kaye SB Combining antiangiogenics to overcome resistance: rationale and clinical experience Clin Cancer Res 2012 18 3750 3761 22547772
   PubMed Web of Science ®Google Scholar
• Olszewski AJ Grossbard ML Kozuch PS The horizon of antiangiogenic therapy for colorectal cancer Oncology (Williston Park) 2005 19 297 306 discussion 306, 308, 317–333 15828549
   PubMed Web of Science ®Google Scholar
• Ellis LM Bevacizumab Nat Rev Drug Discov 2005 Suppl S8 S9 15962523
   PubMedGoogle Scholar
• Rougier P Lepere C Second-line treatment of patients with metastatic colorectal cancer Semin Oncol 2005 32 S48 S54 16399432
   PubMed Web of Science ®Google Scholar
• Giantonio BJ Catalano PJ Meropol NJ Eastern Cooperative Oncology Group Study E3200 Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 J Clin Oncol 2007 25 1539 1544 17442997
   PubMed Web of Science ®Google Scholar
• Saltz LB Clarke S Díaz-Rubio E Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 2008 26 2013 2019 18421054
   PubMed Web of Science ®Google Scholar
• FDA approval for bevacizumab [webpage on the Internet] Bethesda, MD National Cancer Institute Available from: http://www.cancer.gov/cancertopics/druginfo/fda-bevacizumab Accessed August 15, 2013
   Google Scholar
• Díaz-Rubio E Gómez-España A Massutí B Spanish Cooperative Group for the Treatment of Digestive Tumors First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colo-rectal cancer: the phase III MACRO TTD study Oncologist 2012 17 15 25 22234633
   PubMed Web of Science ®Google Scholar
• Moscetti L Nelli F Fabbri MA Maintenance single-agent bevacizumab or observation after first-line chemotherapy in patients with metastatic colorectal cancer: a multicenter retrospective study Invest New Drugs 2013 31 4 1035 1043 23417697
   PubMed Web of Science ®Google Scholar
• Greil R Von Moos R Bennouna J Bevacizumab plus chemotherapy continued beyond first disease progression in patients with metastatic colorectal cancer previously treated with bevacizumab-based therapy: patterns of disease progression and outcomes based on extent of disease in the ML18147 study. 2013 ASCO Annual Meeting J Clin Oncol 2013 31 (Suppl; abstr 3604)
   Google Scholar
• Koopman M Simkens LHJ Ten Tije AJ Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): the phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG). 2013 ASCO Annual Meeting J Clin Oncol 2013 31 (Suppl; abstr 3502)
   Google Scholar
• Evoy KE Abel SR Aflibercept: newly approved for the treatment of macular edema following central retinal vein occlusion Ann Pharmacother 2013 47 819 827 23673531
   PubMed Web of Science ®Google Scholar
• Thomas M Mousa SS Mousa SA Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration Clin Ophthalmol 2013 7 495 501 23503202
   PubMedGoogle Scholar
• Sharma T Dhingra R Singh S Aflibercept: a novel VEGF targeted agent to explore the future perspectives of anti-angiogenic therapy for the treatment of multiple tumors Mini Rev Med Chem 2013 13 530 540 23317499
   PubMed Web of Science ®Google Scholar
• Chu QS Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors Expert Opin Biol Ther 2009 9 263 271 19236257
   PubMed Web of Science ®Google Scholar
• Roy H Bhardwaj S Babu M Adenovirus-mediated gene transfer of placental growth factor to perivascular tissue induces angiogenesis via upregulation of the expression of endogenous vascular endothelial growth factor-A Hum Gene Ther 2005 16 1422 1428 16390273
   PubMed Web of Science ®Google Scholar
• Fischer C Mazzone M Jonckx B Carmeliet P FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer 2008 8 942 956 19029957
   PubMed Web of Science ®Google Scholar
• Rini BI Michaelson MD Rosenberg JE Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma J Clin Oncol 2008 26 3743 3748 18669461
   PubMed Web of Science ®Google Scholar
• Gaya A Tse V A preclinical and clinical review of aflibercept for the management of cancer Cancer Treat Rev 2012 38 484 493 22264850
   PubMed Web of Science ®Google Scholar
• Fetterly GJ Aras U Lal D Murphy M Meholick PD Wang ES Development of a preclinical PK/PD model to assess antitumor response of a sequential aflibercept and doxorubicin-dosing strategy in acute myeloid leukemia AAPS J 2013 15 3 662 673 23550025
   PubMed Web of Science ®Google Scholar
• Van Cutsem E Tabernero J Lakomy R Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen J Clin Oncol 2012 30 3499 3506 22949147
   PubMed Web of Science ®Google Scholar
• Sun W Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy J Hematol Oncol 2012 5 63 23057939
   PubMed Web of Science ®Google Scholar
• Bennouna J Sastre J Arnold D ML18147 Study Investigators Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial Lancet Oncol 2013 14 29 37 23168366
   PubMed Web of Science ®Google Scholar
• Bou-Assaly W Mukherji S Cetuximab (erbitux) AJNR Am J Neuroradiol 2010 31 626 627 20167650
   PubMed Web of Science ®Google Scholar
• Vincenzi B Zoccoli A Pantano F Venditti O Galluzzo S Cetuximab: from bench to bedside Curr Cancer Drug Targets 2010 10 80 95 20088790
   PubMed Web of Science ®Google Scholar
• Khoukaz T Administration of anti-EGFR therapy: a practical review Semin Oncol Nurs 2006 22 20 27 16616283
   PubMedGoogle Scholar
• Tortora G Caputo R Pomatico G Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth Clin Cancer Res 1999 5 875 881 10213224
   PubMed Web of Science ®Google Scholar
• Mandal M Adam L Mendelsohn J Kumar R Nuclear targeting of Bax during apoptosis in human colorectal cancer cells Oncogene 1998 17 999 1007 9747879
   PubMed Web of Science ®Google Scholar
• Kurai J Chikumi H Hashimoto K Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines Clin Cancer Res 2007 13 1552 1561 17332301
   PubMed Web of Science ®Google Scholar
• Kimura H Sakai K Arao T Shimoyama T Tamura T Nishio K Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor Cancer Sci 2007 98 1275 1280 17498200
   PubMed Web of Science ®Google Scholar
• Bose D Zimmerman LJ Pierobon M Chemoresistant colorectal cancer cells and cancer stem cells mediate growth and survival of bystander cells Br J Cancer 2011 105 1759 1767 22045189
   PubMed Web of Science ®Google Scholar
• Feng Y Dai X Li X EGF signalling pathway regulates colon cancer stem cell proliferation and apoptosis Cell Prolif 2012 45 413 419 22925500
   PubMed Web of Science ®Google Scholar
• Chung KY Shia J Kemeny NE Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry J Clin Oncol 2005 23 1803 1810 15677699
   PubMed Web of Science ®Google Scholar
• Jonker DJ O’Callaghan CJ Karapetis CS Cetuximab for the treatment of colorectal cancer N Engl J Med 2007 357 2040 2048 18003960
   PubMed Web of Science ®Google Scholar
• Sobrero AF Maurel J Fehrenbacher L EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer J Clin Oncol 2008 26 2311 2319 18390971
   PubMed Web of Science ®Google Scholar
• Borner M Koeberle D Von Moos R Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK Ann Oncol 2008 19 1288 1292 18349029
   PubMed Web of Science ®Google Scholar
• Cunningham D Humblet Y Siena S Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 2004 351 337 345 15269313
   PubMed Web of Science ®Google Scholar
• Cersosimo RJ Management of advanced colorectal cancer, part 1 Am J Health Syst Pharm 2013 70 395 406 23413162
   PubMed Web of Science ®Google Scholar
• Cersosimo RJ Management of advanced colorectal cancer, part 2 Am J Health Syst Pharm 2013 70 491 506 23456402
   PubMed Web of Science ®Google Scholar
• Hubbard JM Alberts SR Alternate dosing of cetuximab for patients with metastatic colorectal cancer Gastrointest Cancer Res 2013 6 47 55 23745159
   PubMedGoogle Scholar
• Bokemeyer C Van Cutsem E Rougier P Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic col-orectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials Eur J Cancer 2012 48 1466 1475 22446022
   PubMed Web of Science ®Google Scholar
• Tejpar S Celik I Schlichting M Sartorius U Bokemeyer C Van Cutsem E Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab J Clin Oncol 2012 30 3570 3577 22734028
   PubMed Web of Science ®Google Scholar
• Brand TM Iida M Wheeler DL Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab Cancer Biol Ther 2011 11 777 792 21293176
   PubMed Web of Science ®Google Scholar
• Kopper L Panitumumab: an arrow on target Pathol Oncol Res 2010 16 143 148 20432075
   PubMed Web of Science ®Google Scholar
• Cartenì G Fiorentino R Vecchione L Chiurazzi B Battista C Panitumumab a novel drug in cancer treatment Ann Oncol 2007 18 Suppl 6 vi16 vi21 17591813
   PubMedGoogle Scholar
• Vectibix®(panitumumab) [package insert] Thousand Oaks, CA Amgen Inc 2010
   Google Scholar
• Agency EM Vectibix European Public Assessment Report, Summary of Product Characteristics 2010 Available from: http://www.emaeuropa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000741/WC500047710pdf Accessed August 15, 2013
   Google Scholar
• Douillard JY Siena S Cassidy J Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study J Clin Oncol 2010 28 4697 4705 20921465
   PubMed Web of Science ®Google Scholar
• Peeters M Price TJ Cervantes A Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer J Clin Oncol 2010 28 4706 4713 20921462
   PubMed Web of Science ®Google Scholar
• Cohn AL Shumaker GC Khandelwal P An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer Clin Colorectal Cancer 2011 10 171 177 21855038
   PubMed Web of Science ®Google Scholar
• Kohne CH Hofheinz R Mineur L First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer J Cancer Res Clin Oncol 2012 138 65 72 21960318
   PubMed Web of Science ®Google Scholar
• Wilhelm SM Dumas J Adnane L Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity Int J Cancer 2011 129 245 255 21170960
   PubMed Web of Science ®Google Scholar
• Aprile G Macerelli M Giuliani F Regorafenib for gastrointestinal malignancies: from preclinical data to clinical results of a novel multi-target inhibitor BioDrugs 2013 27 213 224 23435872
   PubMed Web of Science ®Google Scholar
• Abou-Elkacem L Arns S Brix G Regorafenib inhibits growth, angiogenesis and metastasis in a highly aggressive, orthotopic colon cancer model Mol Cancer Ther 2013 12 7 1322 1331 23619301
   PubMed Web of Science ®Google Scholar
• Schultheis B Folprecht G Kuhlmann J Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study Ann Oncol 2013 24 1560 1567 23493136
   PubMed Web of Science ®Google Scholar
• George S Wang Q Heinrich MC Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial J Clin Oncol 2012 30 2401 2407 22614970
   PubMed Web of Science ®Google Scholar